SLC43A3 is a biomarker of sensitivity to the telomeric DNA damage mediator 6-thio-2′-deoxyguanosine

Ilgen Mender, Kimberly Batten, Michael Peyton, Aishwarya Vemula, Crystal Cornelius, Luc Girard, Boning Gao, John D. Minna, Jerry W. Shay

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Cell membrane transporters facilitate the passage of nucleobases and nucleosides for nucleotide synthesis and metabolism, and are important for the delivery of nucleoside analogues used in anticancer drug therapy. Here, we investigated if cell membrane transporters are involved in the cellular uptake of the nucleoside analogue DNA damage mediator 6-thio-2′-deoxyguanosine (6-thio-dG). A large panel of non-small cell lung cancer (NSCLC) cell lines (73 of 77) were sensitive to 6-thio-dG; only four NSCLC lines were resistant to 6-thio-dG. When analyzed by microarray and RNA sequencing, the resistant NSCLC cell lines clustered together, providing a molecular signature for patients that may not respond to 6-thiodG. Significant downregulation of solute carrier family 43 A3 (SLC43A3), an equilibrative nucleobase transporter, was identified as a candidate in this molecular resistance signature. High levels of SLC43A3 mRNA predicted sensitivity to 6-thio-dG and therefore SLC43A3 could serve as a promising biomarker for 6-thio-dG sensitivity in patients with NSCLC. Significance: These findings identify a biomarker of resistance to the telomeric DNA damage mediator 6-thio-2′-deoxyguanosine.

Original languageEnglish (US)
Pages (from-to)929-936
Number of pages8
JournalCancer research
Issue number5
StatePublished - Mar 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'SLC43A3 is a biomarker of sensitivity to the telomeric DNA damage mediator 6-thio-2′-deoxyguanosine'. Together they form a unique fingerprint.

Cite this